A Study of Novel Oncology Therapies in Combination with FOLFOX and Bevacizumab in Metastatic Microsatellite-Stable Colorectal Cancer
Ontology highlight
ABSTRACT: Primary objectives: Part 1: To evaluate the safety and tolerability profile of FOLFOX + bevacizumab + novel oncology therapy combinations
Part 2: To compare the efficacy of FOLFOX + bevacizumab + novel oncology therapy combinations versus FOLFOX + bevacizumab
Primary endpoints: Part 1: Incidence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), laboratory findings, and vital signs
Part 2: Objective response (OR) per RECIST v1.1
DISEASE(S): Cáncer Colorrectal Con Microsatélites Estables Metastásico,Metastatic Colorectal Cancer,Metastatic Microsatellite-stable Colorectal Cancer
PROVIDER: 2538990 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA